July 17, 2023
Ophthorobotics Strengthens Patent Position For Its Lead Product IID
Klosters, Switzerland, July 10, 2023 –
Ophthorobotics, a preclinical-stage medtech company developing a first in class automated intravitreal injection system , announced today that it was granted a key patent for its unique drug delivery system by the european patent office (EPO).
The patent is valid through 2043 with eefect for all memebr states.
„The company has now a strong patent portfolio protecting its robotic-assisted intravitreal drug delivery system in all leading medical device markets,” said Bernhard Günther, CEO and Chairman of the Board. „This new patent expand the IP protection for our protoype IID even further and is critical in harnessing the medical and economic potential of this ophthalmic innovativion. We are currently preparing for a Series A funding to enter into clinical trial by mid of 2024.“
About Ophthorobotics
Ophthorobotics is pioneering the development of a remote-controlled robotic system for intravitreal injections, specifically for the treatment of age-related macula degeneration. A prototype of ist lead product IID is currently in preclinical trials at the ETH in Zurich. Age related macula degeneration (AMD) is the primary cause of blindness in industrialized countries with a blindness prevalence of 8.7%. In the past only the neovascular form of the disease was treatable. However, a new drug for the intravitreal treatment of geographic athropy (GA), a subform of dry AMD, has been recently approved by FDA and might further increase the need for intravitreal injections significantly.
For further information please contact:
Ophthorobotics AG
Bernhard Günther
Chief Executive Officer & Chairman of the Board
bguenther@ophthorobotics.com
